7707
CMSC, Inc. designs and manufactures integrated circuits in Taiwan, Japan, South Korea, and internationally. The company's product portfolio includes modules, system-in-packages, PCBs, and customized systems, as well as engages in the physical design, optimization, and SOC integration service; analog IC front-end and back-end design service; and IC chip engineering and mass production management. … Read more
7707 (7707) - Total Liabilities
Latest total liabilities as of June 2025: NT$387.75 Million TWD
Based on the latest financial reports, 7707 (7707) has total liabilities worth NT$387.75 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
7707 - Total Liabilities Trend (2020–2024)
This chart illustrates how 7707's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
7707 Competitors by Total Liabilities
The table below lists competitors of 7707 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shin Ruenn Development Co Ltd
TWO:6186
|
Taiwan | NT$12.22 Billion |
|
Pollard Banknote Limited
PINK:PBKOF
|
USA | $325.20 Million |
|
Morepen Laboratories Limited
NSE:MOREPENLAB
|
India | ₹5.39 Billion |
|
SKYX Platforms Corp
NASDAQ:SKYX
|
USA | $57.25 Million |
|
AC Immune Ltd
NASDAQ:ACIU
|
USA | $109.16 Million |
|
Nex Point Public Company Limited
BK:NEX
|
Thailand | ฿2.00 Billion |
|
Grand Fortune Securities Co Ltd
TWO:6026
|
Taiwan | NT$6.91 Billion |
|
Duopharma Biotech Bhd
KLSE:7148
|
Malaysia | RM690.68 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down 7707's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 7707's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 7707 (2020–2024)
The table below shows the annual total liabilities of 7707 from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$346.31 Million | -11.10% |
| 2023-12-31 | NT$389.54 Million | +2.16% |
| 2022-12-31 | NT$381.31 Million | +99.96% |
| 2021-12-31 | NT$190.69 Million | +49.37% |
| 2020-12-31 | NT$127.67 Million | -- |